211 related articles for article (PubMed ID: 26829942)
1. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
Ghabri S; Hamers FF; Josselin JM
Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
[TBL] [Abstract][Full Text] [Related]
2. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
Hamers FF; Ghabri S; Le Gales C
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
[TBL] [Abstract][Full Text] [Related]
3. A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.
Carroll C; Kaltenthaler E; FitzGerald P; Boland A; Dickson R
Health Policy; 2011 Oct; 102(2-3):136-44. PubMed ID: 21763025
[TBL] [Abstract][Full Text] [Related]
4. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
5. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
Alshreef A; Jenks M; Green W; Dixon S
Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
[TBL] [Abstract][Full Text] [Related]
6. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
Meregaglia M; Nicod E; Drummond M
Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
[TBL] [Abstract][Full Text] [Related]
7. Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).
Ghabri S; Hamers FF; Josselin JM; Harousseau JL
Value Health; 2014 Nov; 17(7):A441-2. PubMed ID: 27201181
[No Abstract] [Full Text] [Related]
8. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
9. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
Chauhan D; Miners AH; Fischer AJ
Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
[TBL] [Abstract][Full Text] [Related]
11. A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.
Kaltenthaler EC; Dickson R; Boland A; Carroll C; Fitzgerald P; Papaioannou D; Akehurst R
BMJ Open; 2012; 2(1):e000562. PubMed ID: 22318664
[TBL] [Abstract][Full Text] [Related]
12. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
Shiroiwa T; Fukuda T; Ikeda S; Takura T
Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
[TBL] [Abstract][Full Text] [Related]
13. How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea.
Bae S; Lee J; Bae EY
Front Pharmacol; 2022; 13():884769. PubMed ID: 35652044
[No Abstract] [Full Text] [Related]
14. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation approaches for new technology.
Papatheofanis FJ
IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
[No Abstract] [Full Text] [Related]
16. A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty.
Martelli N; Devaux C; van den Brink H; Pineau J; Prognon P; Borget I
PLoS One; 2015; 10(12):e0144892. PubMed ID: 26661078
[TBL] [Abstract][Full Text] [Related]
17. Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future.
Mauskopf J
Value Health; 2019 May; 22(5):570-574. PubMed ID: 31104736
[TBL] [Abstract][Full Text] [Related]
18. FACTORS INFLUENCING REIMBURSEMENT OF MEDICAL DEVICES IN FRANCE.
Loge P; Delalande F; Reymond MC; Germain S
Int J Technol Assess Health Care; 2015; 31(6):399-406. PubMed ID: 26868190
[TBL] [Abstract][Full Text] [Related]
19. MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS.
Akpinar I; Jacobs P; Husereau D
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):86-9. PubMed ID: 25989920
[TBL] [Abstract][Full Text] [Related]
20. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
